Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Partnership Established to Probe the Inner Workings of Colon Cancer

By BiotechDaily International staff writers
Posted on 01 Jul 2013
Image: Eearly stage colon cancer using GE’s cancer mapping technology (Photo courtesy of GE).
Image: Eearly stage colon cancer using GE’s cancer mapping technology (Photo courtesy of GE).
New cancer mapping technology has been designed to provide a more detailed study of cancer cells and may provide better clues into how colon cancer develops, progresses, and how it can be curbed.

Vanderbilt University (Nashville, TN, USA) is collaborating with GE Global Research (Niskayuna, NY, USA), the technology development arm for the General Electric Co. (Fairfield, CT, USA), to better define, at the cellular level, how colon tumors form and develop.

Supported by a five-year, USD 3.75 million grant from the Office of the Director of the National Institutes of Health (NIH; Bethesda, MD, USA), the research will evaluate GE’s innovative cancer mapping technology, an automated platform that can probe and analyze up to 60 different disease markers, including proteins and messenger RNAs, in a single tissue sample. The capability to examine dozens of markers at one time provides a more complete outlook of the actual mechanisms of cancer. Currently, a diagnosis of cancer and the choice of which therapy to prescribe are based on the histology of the tumor, and in some cases, the expression of just one or two disease markers inside a patient’s tumor.

The GE-Vanderbilt project, led by GE scientists Michael Gerdes, PhD and Kashan Shaikh, PhD, and Robert Coffey, MD, a professor of cancer research at Vanderbilt, will examine how intestinal stem cells of the colon contribute to tumor formation and progression, and the signaling pathways associated with the disease.

“With GE’s cancer mapping technology, we’re enabling cancer to be viewed in ways it couldn’t previously be seen such as with the activation of different signaling pathways in specific cells,” said Prof. Gerdes, lead scientist at GE Global Research. “With unprecedented views, we hope will come unprecedented insights that tell us more about how cancer forms, how it progresses, and most importantly, how to defeat it.”

GE scientists have developed cutting-edge technology that allows a single tissue section from a sample that is removed during surgery, to be imaged for biosignatures including expression of dozens of proteins and nucleic acids (RNA and DNA) without destroying the integrity of the sample. “As we have learned, no two patient’s cancer is exactly the same. With colon cancer, some patients exhibit a more aggressive form of the disease compared to other patients,” said John Burczak, advanced technology leader in molecular imaging at GE Global Research. “We want to understand these subtleties, so that one day therapies can even be specifically tailored for each patient.”

Dr. Gerdes added that the goal is to identify “the mechanisms that drive the aggressive nature of the cancer, and the role that cancer stem cells play in therapeutic resistance.”

A major problem in cancer diagnosis is the limited amount of molecular data that is available about a specific cancer. With little information, it is difficult to determine more specific characteristics of cancer that could reveal how fast or gradually it may be growing. New breakthroughs in molecular diagnostics are beginning to change this pattern.

GE’s cancer mapping technology will be tested with investigators at Vanderbilt from the Epithelial Biology Center that Prof. Coffey directs. The Coffey lab recently reported the discovery of a new population of relatively quiescent (inactive) intestinal stem cells. These cells express a protein called Lrig1 that acts as a tumor suppressor. This discovery has “given us an entrée to develop some very robust models of colon cancer,” Prof. Coffey said.

GE Global Research is the hub of technology development for all of GE’s businesses. The company has locations in Niskayuna, NY, USA; San Ramon, CA, USA; Bangalore, India; Shanghai, China; Munich, Germany; and Rio de Janeiro, Brazil.

Related Links:

Vanderbilt University
GE Global Research



Channels

Genomics/Proteomics

view channel
Image: The TheraCyte cell encapsulation device (Photo courtesy of TheraCyte, Inc.).

Encapsulated Human-Insulin-Producing Progenitor Cells Cure Diabetes in Mouse Model

A breakthrough system that allows subcutaneous implantation of encapsulated immature pancreatic cells (beta progenitor cells) was shown to produce enough insulin to correct the symptoms of diabetes in a mouse model.... Read more

Drug Discovery

view channel
Image: Chitosan is derived from the shells of shrimp and other sea crustaceans, including Alaskan pink shrimp, pictured here (Photo courtesy of NOAA - [US] National Oceanic and Atmospheric Administration).

Chitosan Treatment Clears the Way for Antibiotics to Eliminate Recurrent Urinary Tract Infections

Recurrent urinary tract infection was successfully resolved in a mouse model by treatment with the exfoliant chitosan followed by a round of antibiotics. Bacterial urinary tract infection (UTI), most... Read more

Biochemistry

view channel

Mitochondrial Cause of Aging Can Be Reversed

Researchers have found a cause of aging in lab animals that can be reversed, possibly providing an avenue for new treatments for age-related diseases including type 2 diabetes, cancer, muscle wasting, and inflammatory diseases. The researchers plan to begin human trials late 2014. The study, which was published December... Read more

Therapeutics

view channel

Cytokine Identified That Causes Mucositis in Cancer Therapy Patients

The action of the cytokine interleukin 1-beta (IL-1beta) has been found to underlie the onset of mucositis, a common, severe side effect of chemotherapy and irradiation of cancer patients. Mucositis occurs as a result of cell death in reaction to chemo- or radiotherapy. The mucosal lining of the mouth becomes thin, may... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.